within Pharmacolibrary.Drugs.ATC.A;

model A05AX06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.23666666666666666,
    adminDuration  = 600,
    adminMass      = 0.12,
    adminCount     = 1,
    Vd             = 0.118,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011333333333333334,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist developed for the treatment of metabolic diseases, chiefly nonalcoholic steatohepatitis (NASH). It has been investigated in clinical trials but is not approved for clinical use as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol><li><p>Goyal, NP, et al., &amp; Schwimmer, JB (2023). An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic Steatohepatitis. <i>Journal of pediatric gastroenterology and nutrition</i> 77(2) 160â€“165. DOI:<a href=&quot;https://doi.org/10.1097/MPG.0000000000003796&quot;>10.1097/MPG.0000000000003796</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37084342/&quot;>https://pubmed.ncbi.nlm.nih.gov/37084342</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A05AX06;
